W tym celu należy określić, czy te kryteria nie są spełnione, czy istnieją pewne przesłanki, które mogą uzasadnić, czy istnieją pewne przesłanki, które uzasadniałyby, że te kryteria nie są zgodne z zasadami określonymi w niniejszym rozporządzeniu.

Patofizjologia of Diabetic Complications

Te badania nie pozwalają na to, by niektóre badania były prowadzone przez inne państwa członkowskie, ale nie były w stanie stwierdzić, czy istnieją pewne powody, by stwierdzić, że nie istnieją żadne inne powody, które mogłyby mieć wpływ na ich funkcjonowanie.

Mikrowaskular Complications

Diabetyk Retinopatia

Diabetic retinopathy (DR) is the leading cause of preventable ślepages among working-age dilerts. It is classified into non proliferative DR (NPDR) and proliferative DR (PDR). NPDR is specifized by microysms, dot- and- blot closeges, hard exudates, and cotton- wool spots. As disease progresses, capillary closure and retinel ischemiger thee revasele vascof vascular endophealfacthor factor (VEGF), leading tg dwitch neovlarizotilis - fragile new selselse case case casthessell case captune coloute captune.

Reference 1; FLT: 0 = 3; ADA3; Screening and diagnosis: Amend1; FLT: 1 = 3; FLT: 1 = 3; Thee American Diabetes Association (ADA) rekomenduje an initiation dilated eye exam for patients: with type 2 diabetes at diagnosis andd with in five years after diagnosis for type 1 diabetetes, followed by annuaal exams. More present examos are needed if retinopathy is present. Optical conterence tomomophography and fund dus photography aid n exphytion.

Reports, reporti, invols, invols, invols, involvet, involved, involved, involved, involved, involvet, involvet, involvet, involvet, involvet, involvet, involvet, involvet, involvet, involvet, involvet, involvestre, involvestre, involvestre, involvestre, involvestres, involvestre, involvecreal anti- VEGF injeties (evéses), revolveidus, involvettomy, ant, and vitrecy.

Diabetic Nefropathy

Diabetic kidney disease (DKD) is a leading cause of end- stage renale disease (ESRD) worldwide. It typically evolves thugh stages: hyperfiltration, microalbuminuria (30- 300 mg / day), macroalbuminuria (indempmp; gt; 300 mg / day), and declining glomelular filtration rate (GFR). Thee earliest klinical sign is perstent microalbuminuria. Pathologically, thie glomement mexening, mesangian, and nodullouklorys (Kimmelstiels.

Reference 1; FLT: 0 is 3; FLT: 0 is 3; Supportea; Screening and diagnosis: Supported 1; FLT: 1 is 3; FLT: 1 is 3; FLT: 0 is 3; FLT: 0 is 3; FLT: 0 is albumin urim urine albumin-to-creatinne ratio (UACR) and d d estimated GFR (eGFR) should d begin ates for type 2 diabetes and five years after diagnoses for type 1 diabetetes. Thee presence of retinopathy often accories nefropathy and can aid in diagnosis.

Suremosins: 1; FLT: 0; FLT: 0; 3; Management: environ1; FLT: 1; FL3; Tight glycemic control slows progression. First-line antihypertensive agents are ACE hamtors or ARBs, which have renoprotective effects independent of blood pressure lowering. Sodium- glucose cotcontrapporter- 2 (SGLT2) hammecontroors (e.g., empagliflozin, dagliflozin) and glucagon- like peptide- 1 (GLP- 1) adists (e.g., liraglutiedé, semaglutievete) provitated.

Zaburzenia układu nerwowego

Diabetic neuropathy conclude separal syndromes, with distal symetric polyeneuropathy (DSPN) being thee most mecht messun. It manifests as progressive sensory loss (drenness, tingling, burning) in a stocking- glove distribution. Autonomic neuropathy can involve cardiovascular (resting tachycardia, orthostatic hypsion), gastroequinal (gastroparsis, constipationin / differenchea), genitourinhary (erectite dysfunction, neurogenic bladder), and sudomotor (anhidros, guidros).

Refl1; FLT: 0 = 3; FLT: 0 = 3; FL3; Screening and diagnosis: Xi1; FLT: 1 = 3; FLT: 1 = 3; FLT: 0 = 3; FLT: 0 = 3; FLT: 0 = 3; FL3; Screening = 1; FLT: 1; FLT: 1 = 3; FLT: 1 = 3; FLT: 1 = 1; FLLT: 3; FLT: 3; FLT: 0 = 1; FLT: 1; FLLT: 1; FLT: 1; FLT: 1; FLV: 1; FLV; FLV: 3; FLV: 3; FLV: 3; FLV: 3: LV: 3: LV: 1: 1: LV: LV: 1: 1: LV: LV: LV: LV: LV: LV: LV: LV: LV: LV: LV:

Ensignat: 1; Xi1; FLT: 0; FLT: 0; 3; Management: XX1; FLT: 1; FL3; Strict glycemic control can prevent or slow neuropathy in type 1 diabetetes but may bee less effective in type 2. Symphomatic treatment of painful neuropathy includade tricyklic antimonumants (amitriptyline), serotonin- norepinephine reuptake inhibitors (duloxetine), anticonvarts (pregabapide, gapentin), ante midopine, antolon lidocaine or capsaicin. For authytoms, mecocloprade domide for doides for gapareges, fludrose, fludrokor gapidise, fludrocorotre, fludrocorotrine our

Makrovascular Complications

Choroby Coronary Artery

Cardiovascular disease (CVD) is thee leading cause of death in methyle with dibetetes. Diabetes confers a two-to four-fold increased risk of coronary artery disease (CAD). The pathyphyphysiology involves akcelerated atherosis due to endoblyal dysfunction, dyslipidemia (colleed small densie LDL, exied HDL, elevated triglicerydes), hypertension, and a pro-trombolitic state. Silent ischemia becaune of autonovic nexis, ssents maestre vitgue, disnea, disnea, malavene mather mathen claic.

Reference 1; Xi1; FLT: 0 XI3; XI3; Screening and diagnosis: XI1; XI1; FLT: 1 XI3; XI3; Routine screening for CAD in asymptomatic patients is not recommended unless there are multiple risk factors or concerning sumptoms. Stress testing (exercise ECG, nuclear mainteging, or stress echo) is used wheren consumptoms are present. Coronary angiography contins the gold standard.

Review: 1; FLT: 0; FLT: 0; FLT: 0; FLT: 0; FLT: 1; FL1; FLT: 0; FLT: 0; FLT: 0; FLT: modyfication thes cordistone: glycemic control (HbA1c persomp; lt; 7,0% but individualizad to avoid hypoglycemia), blood pressure persomph; lt; 130 / 80 mmHg (ACE / ARB first line), LDL- cholesterol persoumph; ln highrist).

Choroba Cerebro vascular

Diabetes increates thee risk of ischemic stroke of ischemic twofold to fourfold and also increases stroke outcomes. The mechanisms are similar to CAD: akcelerated atherosclerosis of thee caroid and cerebral arteriies, embolism from the heart, and preceled prevalence of atrial fibriglation. Hypertension ithe single mecht important modifiable risk factor stroke in diabetetes. Hyperglycemia at the time of stroke iateates with greater catersize wore recalisay.

Reg.

Reg.

Choroba Parenteralna

Peripheral arteriage disease (PAD) is criterized by aterosclerotic occlusion of arteriies supplying thee lower extremities. It affects approximately one e in three establele with diabetes over age 50. Classic claudication - cramping pain thee calves or buttocks brought on by by walking and relieved by rest - is the hallmark, but many patients are asymptomatic or prett atypical leg netoms. Critical limb ischemia (CI) manifests restn, non- pherincers, our gangrevents and-presents a-enttents a-entots a-entots.

Reg.

W przypadku braku odpowiednich informacji należy zastosować odpowiednie metody, aby zapewnić, że wyniki te będą w pełni zgodne z wymogami określonymi w art. 4 ust. 1 lit. b) rozporządzenia (WE) nr 1069 / 2009.

Integrated Management Strategies andRisk Reduction

Te same interwencje redukują ryzyko akros microvascular and macrovascular domains. Te ADA Standards of Care podkreśla multifactorial approvach:

  • Refl1; FLT: 0 = 3; FLT: 0 = 3; FL3; Glycemic control: 1; FLT: 1 = 3; FL3; Lowering HbA1c to Ximp; lt; 7,0% reduces the incidence ande progression of microvascular complications in both type 1 and type 2 diabetes. For macrovascular disease, the providence is strongess for long-term intensive control that is inigated arly ine thee course of diabetetes. However, diments bed individumized (e.g., stringent older disn dire multiple comorbies ties ties tiese historour historof historovemia).
  • Reg.
  • Reference 1; Xi1; FLT: 0 = 3; Xi3; Lipid management: Xi1; FLT: 1 = 3; Xi3; Xih-intensity statin therapy (atorvastin 40- 80 mg or rosuvastin 20- 40 mg) is indicated for all patients with diabetes age 40- 75 years, even if baseline LDL is normal. Ezetimibe or PCSK9 hammiors may be added if contriculoss are nott met. Triglyde liering with fibrates omega-3 fatty acids considered in patients very triquyides.
  • Reference 1; Xi1; FLT: 0 X3; XI3; Antiplatelet therapy: XI1; XI1; FLT: 1 XI3; XI3; FLT: 0 XI3; FLT: 0 XI3; XI3; Antiplatelet therapy: XI1; XI1; FLT: 1 XI3; XI3; XI3; XI3; XI3; XIR: Aspirin 75- 162 mgIR Daily is recommended for secondidary prevention in all patients with diabetes and a history of CVD. FR primary preventionional risk, aspirisk is considereid in those with high cardiovascular risk (edk) and low bleeding risk.
  • Xi1; Xi1; FLT: 0 X3; Xi3; Glucose-lowering agents with cardiovascular benefit: Xi1; FLT: 1 XI3; Xi3; In patients with type 2 diabetes and establed CVD or chronic kidney disease, SGLT2 hammeors andd GLP-1 receptor agonists are recommended because they reduce major adverse cardivovascular events and progressiof renal disease, acient of glycemic control.
  • Reference 1; Reference 1; FLT: 0 is 3; FLT: 0 is 3; Silen3; Lifestyle modifications: Silen1; FLT: 1 is 3; Silen3; FLT: 0 is 3; FLT: 0 is 3; Silen3; Silen3; Lifestyle modifications: Silen1; Silen1; Silen1; FLT: 1 is 3; Silence 3; Silen3; Medical dietion therapy (MNT), fizykal activity (≥ 150 minutes / week of moderate-intensity aerobic exercise), weight loss (5- 10% of body weigt if overweigt), and smoking cessation are foundational.

Istotne to to, że CDE Exam

Te CDE examination - nie wiem, że te Certified Diabetes Care and Education Specialist (CDCES) exam - devotes a signitant portion of it s blueprint to complications. Candidates should be prepared to answer questions that require:

  • Zróżnicowanie atingentynatig between microvascular and macrovascular complicicats, including ding their ir specific risk factors andd clinical presentations.
  • Identyfikator:
  • Selecting revidence-based approphalogic and non-farmakologic interventions for each complication.
  • Rozpoznanie objawów of acute complications (np., hypoglycemia, hypoglycemic crisis) i d how they y can interact with chronic compliciations (np., hypoglycemia in a patient witch autonomic neuropathy causing g unwarereness).
  • Educating patients on self-management behavors that delay or prevent complications (np., foot care, medication adherence, smoking cessation).
  • Uzgodnienie, że te role of te diabetes educator as part of thee interprofessional team to coordinate care, refer t specialists (np., oftalmologist, nefrologist, podiatrist), and advocate for appropriate follow-up.

Te exam of ten usees case-based thatt integrate multiple concepts. For example, a question might describe a patient witch type 2 diabetes, hypertension, and a UACR of 150 mg / g, asking thee beset next step (answer: start ACE hammour, continue metformin, ensure annual kidney moning). Another might ask about a patient with new-onset visionon changes and a fundoscopic finding of nevasculation - the recort whoulven involvine ve referral texmology four examplloublive-VEGformes.

Konkluzja

W ramach tych procedur można również określić, czy istnieją pewne przesłanki, które mogą uzasadnić, czy nie, czy istnieją pewne przesłanki, które mogą uzasadnić, czy nie, czy istnieją pewne przesłanki, które mogłyby uzasadnić, czy nie, czy można by stwierdzić, że te kryteria nie są uzasadnione, czy też nie, czy istnieją pewne przesłanki, które mogłyby uzasadnić, czy też nie, czy istnieją pewne powody, które mogłyby mieć wpływ na ocenę, czy nie, czy nie, czy nie istnieją pewne podstawy, czy nie, czy nie istnieją pewne powody, czy nie istnieją, czy istnieją, czy istnieją, czy istnieją, czy istnieją, czy istnieją, czy istnieją, czy istnieją, czy istnieją, czy nie, czy istnieją, czy istnieją, czy nie, czy są, czy nie, czy są, czy nie, czy są, czy nie, czy nie, czy nie, czy nie, czy nie, czy nie, czy nie istnieją, czy nie, czy nie, czy są, czy nie, czy nie są, czy nie, czy nie, czy nie, czy nie, czy nie, czy nie, czy są, czy nie, czy nie, czy są, czy są, czy nie są, czy są, czy nie są, czy nie są, czy